Suppression of HIF-1α expression and radiation resistance in acute hypoxic conditions

Experimental and Therapeutic Medicine

Volumn 3, Issue 1, 2012, Pages 141-145

  Oike, Takahiro ^a   Suzuki, Yoshiyuki ^a   Al Jahdari, Wael ^a   Mobaraki, Abdulelah ^a   Saitoh, Jun Ichi ^b   Torikai, Kohta ^b   Shirai, Katsuyuki ^a   Nakano, Takashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Acute hypoxia; Hypoxia inducible factor 1 ; Radiation resistance; YC 1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIFICIGUAT;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IONIZING RADIATION; LUNG ADENOCARCINOMA; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84855393752     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.373     Document Type: Article

References (28)

1. Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004.
2. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838, 1988.
3. Kallman RF: The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105: 135-412, 1972.
4. Nordsmark M, Overgaard M and Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39, 1996.
5. 2 tension measurements. Cancer Res 51: 3316-22, 1991.
6. Yeh KA, Biade S, Lanciano RM, Brown DQ, Fenning MC, Babb JS, et al: Polarographic needle electrode measurements of oxygen in rat prostate carcinomas. Int J Radiat Oncol Biol Phys 33: 111-118, 1995.
7. Suzuki Y, Nakano T, Ohno T, Kato S, Niibe Y, Morita S, et al: Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. Int J Gynecol Cancer 16: 306-311, 2006.
8. Hall EJ and Giaccia AJ: Oxygen effect and reoxygenation. In: Radiobiology for the Radiologist. McAllister L (ed). 6th edition. Lippincott Williams & Wilkins, Philadelphia, PA, pp85-105, 2006.
9. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
10. Trotter MJ, Chaplin DJ, Durand RE and Olive PL: The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 16: 931-934, 1989.
11. Tufto I and Rofstad EK: Transient perfusion in human melanoma xenografts. Br J Cancer 71: 789-793, 1995.
12. Cárdenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S and Dewhirst MW: The pervasive presence of fluctuating oxygenation in tumors. Cancer Res 68: 5812-5819, 2008.
13. Brahimi-Horn MC and Pouysségur J: HIF at a glance. J Cell Sci 122: 1055-1057, 2009.
14. Rankin EB and Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685, 2008.
15. Huang LE, Arany Z, Livingston DM and Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
16. Hofer T, Desbaillets I, Höpfl G, Gassmann M and Wenger RH: Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1 alpha activation cascade: implications for HIF-1 alpha gene therapy. FASEB J 15: 2715-2717, 2001.
17. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M and Wenger RH: Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha. J Cell Sci 112: 1203-1212, 1999.
18. Semenza GL: Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131: 207-214, 1998.
19. Xueguan L, Xiaoshen W, Yongsheng Z, Chaosu H, Chunying S and Yan F: Hypoxia inducible factor-1alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol 20: 606-612, 2008.
20. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al: Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
21. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93: 309-314, 2001.
22. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000.
23. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rössler K, Prodinger A, et al: Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 92: 165-171, 2001.
24. Furusawa Y, Fukutsu K, Aoki M, Itsukaichi H, Eguchi-Kasai K, Ohara H, et al: Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated (3)He-, (12)C- and (20)Ne-ion beams. Radiat Res 154: 485-496, 2000.
25. Vordermark D, Katzer A, Baier K, Kraft P and Flentje M: Cell type-specific association of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein accumulation and radiobiologic tumor hypoxia. Int J Radiat Oncol Biol Phys 58: 1242-1250, 2004.
26. Arvold ND, Guha N, Wang D, Matli M, Deen DF, Warren RS, et al: Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1 in vitro. Int J Radiat Oncol Biol Phys 62: 207-212, 2005.
27. Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, Beyer M, et al: Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer 7: 213-220, 2007.
28. Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, Shinomiya K, et al: The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360: 791-796, 2007.